María Cristina Furrianca

Dr. María Cristina Furrianca


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
DADiego Arauna
Diego Arauna
MFMaría Cristina Furrianca
María Cristina Furrianca
YEYolanda Espinosa-Parrilla
Yolanda Espinosa-Parrilla
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes
Marcelo AlarcónMarcelo Alarcón
Marcelo Alarcón
IPIvan Palomo
Ivan Palomo
Diet, particularly the Mediterranean diet, has been considered as a protective factor against the development of cardiovascular diseases, the main cause of death in the world. Aging is one of the major risk factors for cardiovascular diseases, which have an oxidative pathophysiological component, being the mitochondria one of the key organelles in the regulation of oxidative stress. Certain natural bioactive compounds have the ability to regulate oxidative phosphorylation, the production of reactive oxygen species and the expression of mitochondrial proteins; but their efficacy within the mitochondrial physiopathology of cardiovascular diseases has not been clarified yet. The following review has the purpose of evaluating several natural compounds with evidence of mitochondrial effect in cardiovascular disease models, ascertaining the main cellular mechanisms and their potential use as functional foods for prevention of cardiovascular disease and healthy aging.

30 November 2024 in Tropical Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
MFMaría Cristina Furrianca
María Cristina Furrianca
VUVeronica Ulloa
Veronica Ulloa
HSHéctor Sandoval
Héctor Sandoval
HRHector Retamal-Matus
Hector Retamal-Matus
AFAlejandra Fernández-Elgueta
Alejandra Fernández-Elgueta
JBJuan Borquez
Juan Borquez
Dyslipidemia is a chronic disease characterized by elevated blood lipid levels treatable with statins.However, long-term statin use may have adverse effects, such as liver damage and memory loss.Nevertheless, plants and their active compounds effectively and safely improve lipid profiles. Thisreview aims to update information on the genus Berberis as a hypolipidemic agent, assess the effects ofthese extracts on organisms and provide evidence supporting the use of these natural products inpharmaceutical drugs. Berberis species with therapeutic potential include B. vulgaris, B. integerrima, B.aristata, B. lycium, B. orthobotrys, and B. calliobotrys, which have shown promising results in reducinglipid levels in humans and other animals. In addition, combining berberine with nutraceuticals mayimprove its intestinal absorption, enhancing its lipid-lowering effect. Herbal medicine studies suggestthat Berberis has a high potential for the management of hyperlipidemia.